Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2019.1608821
Abstract: ABSTRACT Introduction: JAK, which constitutively binds to some cytokine receptors, plays an important role in cytokine signaling. While JAK is comprised of JAK1, JAK2, JAK3, and Tyk2, more than 40 types of cytokines transmit signals… read more here.
Keywords: rheumatoid arthritis; treatment rheumatoid; baricitinib treatment;
Baricitinib treatment of severe chronic hand eczema: Two case reports
Sign Up to like & getrecommendations! Published in 2022 at "Contact Dermatitis"
DOI: 10.1111/cod.14039
Abstract: 1. Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol. 2020;21(7):e342-e349. 2. Huang J, Xu J, Chen Y, et al. Camrelizumab versus… read more here.
Keywords: severe chronic; chronic hand; treatment severe; baricitinib treatment ... See more keywords
Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1008392
Abstract: Background Livedoid vasculopathy is a rare, chronic, and recurrent disease with limited effective treatments. Its etiopathogenesis remains incompletely understood. Baricitinib, a selective Janus kinase 1 and 2 inhibitor, has been used to treat rheumatoid arthritis… read more here.
Keywords: refractory livedoid; treatment refractory; baricitinib treatment; treatment ... See more keywords